Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 13Neoplasms 11Neuroendocrine Tumors 10Recurrence 8Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Prostatic Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Hodgkin Disease 4Head and Neck Neoplasms 4Glioblastoma 4Waldenstrom Macroglobulinemia 3Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3

Interventions

defactinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Phase IB × Everolimus × Clear all
NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

Data powered by HemOnc (CC BY 4.0) Colophon âš¡